Boosting anti-leukemia cytotoxicity of CD4 and CD8 T cells through combined inhibition of MEK and HDAC [0.03%]
通过联合抑制MEK和HDAC增强CD4和CD8 T细胞的抗白血病细胞毒性
Meher Bolisetti Gayatri,Bei Jia,Anthony J Veltri et al.
Meher Bolisetti Gayatri et al.
Acute myeloid leukemia (AML) is an aggressive blood cancer with a 5-year overall survival rate of ~30%. Although immunotherapies engaging T cells demonstrate remarkable success in treating many solid tumors and blood cancers, they show litt...
Recipient Endothelial IRF1 mediates IFNγ-driven tissue tolerance in mouse models of acute Graft-versus-Host Disease [0.03%]
受者内皮细胞IRF1介导急性移植物抗宿主病小鼠模型中的IFNγ驱动的组织耐受性
Lotus Neidemire-Colley,Rathan Kumar,Elizabeth Ar Garfinkle et al.
Lotus Neidemire-Colley et al.
Recipient endothelial cells (ECs) actively respond to inflammation during allogeneic hematopoietic cell transplant (allo-HCT), yet mechanisms by which ECs influence acute graft-versus-host-disease (GVHD) pathology remain incompletely define...
Functional restoration of immune defects in STAT1 gain-of-function disease following stem cell gene editing [0.03%]
STAT1功能获得性疾病的造血干细胞基因编辑修复免疫缺陷功能
Robert Torrance,Katharine Orf,Nathan White et al.
Robert Torrance et al.
Germline gain-of-function (GOF) mutations in the signal transducer and activator of transcription 1 (STAT1) gene cause a dominantly inherited inborn error of immunity (IEI) characterized by chronic mucocutaneous candidiasis, autoimmunity, s...
DRP1-mediated mitochondrial fragmentation is a druggable vulnerability in multiple myeloma [0.03%]
DRP1介导的线粒体片段化是治疗多发性骨髓瘤的一个可药物作用的弱点
Maria Eugenia Gallo Cantafio,Noemi Puccio,Roberta Torcasio et al.
Maria Eugenia Gallo Cantafio et al.
Mitochondrial dynamics is a key regulator of cellular homeostasis, orchestrating metabolic reprogramming that fuels tumor progression and treatment resistance. In multiple myeloma (MM), however, the functional relevance of mitochondrial rem...
A first-in-class RNA degrader reduces c-MYC expression and myeloma cell survival in preclinical models [0.03%]
一种新型的RNA降解剂通过降低c-MYC表达和多发性骨髓瘤细胞存活在临床前模型中发挥作用
Domenico Maisano,Tenghui Wang,Steffen Benham Kulp et al.
Domenico Maisano et al.
The c-MYC (MYC) oncogene is a critical driver of multiple myeloma (MM), however, direct targeting of the MYC protein has proven challenging due to its intrinsic structural disorder. In this study, we evaluated the biological activity and mo...
Characteristics of Donor and Recipient Clonal Hematopoiesis in Nonmyeloablative Transplant for Sickle Cell Disease [0.03%]
非清髓移植治疗镰状细胞病供体和受体克隆型血液发生的特征
Lachelle D Weeks,Donna S Neuberg,Emily M Limerick et al.
Lachelle D Weeks et al.
Sickle cell disease (SCD) is an inherited hemoglobinopathy characterized by chronic hemolytic anemia, painful vaso-occlusive episodes, and end-organ damage. Cellular therapies, including allogeneic hematopoietic cell transplant (allo-HCT) a...
1F10, a λ Light Chain Amyloid-Specific Monoclonal Antibody for Targeted Therapy of AL Amyloidosis [0.03%]
靶向治疗AL型淀粉样变症的1F10抗λ轻链淀粉样蛋白单克隆抗体
Jing Fu,Michael S Hughes,Gavreel F Kalantarov et al.
Jing Fu et al.
Light chain (AL) amyloidosis is a fatal plasma cell dyscrasia characterized by the overproduction of misfolded l or k immunoglobulin light chains (LCs) produced by clonal plasma cells, which aggregate into amyloid fibrils that deposit in ti...
Clinical and Genomic Convergence of High-Risk CCUS and Lower-Risk Myelodysplastic Syndromes/Neoplasms [0.03%]
高危CCUS与低危骨髓增生异常综合征/肿瘤的临床和基因组汇聚点
Zhuoer Xie,Zena R Komrokji,Michael Otterstatter et al.
Zhuoer Xie et al.
Clonal cytopenia of undetermined significance (CCUS) is defined by unexplained cytopenias with myeloid-associated somatic mutations not meeting diagnostic criteria for myelodysplastic syndromes/neoplasms (MDS) yet carries a highly risk-stra...
Prime editing enables drug-controllable T-cell therapies with clinical immunosuppression [0.03%]
基于先导编辑的药物可控CAR-T细胞疗法用于临床级免疫抑制
Esther Bandala-Sanchez,Emma V Petley,Kerry Ramsay et al.
Esther Bandala-Sanchez et al.
Current cell and gene therapies lack clinically practical mechanisms to selectively promote or suppress therapeutic cells in vivo, a limitation that is particularly acute in patients requiring ongoing immunosuppression. This includes gene t...